Impact of a Booster Course of Antenatal Steroids on Neonatal Outcome in Patients With Premature Rupture of the Membranes

NCT ID: NCT02469519

Last Updated: 2022-12-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

194 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-03-03

Study Completion Date

2022-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial hopes to prospectively evaluate the impact of one versus two courses of antenatal steroids on the incidence of major neonatal morbidity in pregnant women with pre-labor premature rupture of the membranes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multicenter randomized double blinded trial that hopes to prospectively evaluate the impact of one versus two courses of antenatal steroids on the incidence of major neonatal morbidity including respiratory distress syndrome in pregnant women with a singleton gestation between 24w0d - 32w6d gestation who have documented premature rupture of the membranes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Premature Birth

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Betamethasone - ACTIVE

Booster Course of Antenatal Steroids consists of Betamethasone \[12 mg intramuscular injection, 24 hours apart X 2 doses\] or if unavailable may give Dexamethasone \[6 mg intramuscularly 12 hours apart x 4 doses\]

Group Type EXPERIMENTAL

Betamethasone - ACTIVE

Intervention Type DRUG

antenatal corticosteroid (ACS) is to be given by injection 24 hours apart for two doses.

normal saline - PLACEBO

Normal saline of equivalent volume given intramuscularly at the equivalent dosing regimes listed in experimental arm.

Group Type PLACEBO_COMPARATOR

Normal Saline - PLACEBO

Intervention Type OTHER

normal saline of the same quantity as with the experimental drug is to be given by injection 24 hours apart for two doses

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Betamethasone - ACTIVE

antenatal corticosteroid (ACS) is to be given by injection 24 hours apart for two doses.

Intervention Type DRUG

Normal Saline - PLACEBO

normal saline of the same quantity as with the experimental drug is to be given by injection 24 hours apart for two doses

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

antenatal corticosteroid dexamethasone NS

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants age 18 years or older
* 24w0d to 32w6d weeks gestation
* Singleton pregnancy
* Received first course of ACS at or prior to 31w6d gestation
* Began first course of ACS at least 7 days ( =/\> 168 hours) prior to randomization
* Expectant management planned
* Premature Ruptured membranes (PROM) before onset of labor

Exclusion Criteria

* Known major fetal anomalies
* Multiple gestation
* Not a candidate for expectant management
* Clinical chorioamnionitis (two or more of the following: temperature \> 38.0 degrees centigrade; uterine tenderness; foul smelling vaginal discharge or amniotic fluid; maternal tachycardia \>100 bpm; fetal tachycardia \>160 bpm; maternal White Blood Cell (WBC) count \>20 X 109/L; C-Reactive Protein (CRP) \> 5.9
* Already receiving corticosteroids for another condition
* Any contraindications to the maternal use of corticosteroids
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pediatrix

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Richard Porreco, MD

Role: PRINCIPAL_INVESTIGATOR

Pediatrix

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of South Alabama Medical Center

Mobile, Alabama, United States

Site Status

Phoenix Perinatal Associates

Phoenix, Arizona, United States

Site Status

Long Beach Memorial Medical Center

Long Beach, California, United States

Site Status

Good Samaritan Hospital

San Jose, California, United States

Site Status

Presbyterian/St Luke's Hospital

Denver, Colorado, United States

Site Status

Ochsner Clinic Foundation

New Orleans, Louisiana, United States

Site Status

Lousiana State University Health Science

Shreveport, Louisiana, United States

Site Status

University of Tennessee Medical Center

Knoxville, Tennessee, United States

Site Status

Swedish Medical Center

Seattle, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Porreco R, Garite TJ, Combs CA, Maurel K, Huls CK, Baker S, Fortner KB, Longo SA, Nageotte M, Lewis D, Tran L; Obstetrix Collaborative Research Network. Booster course of antenatal corticosteroids after preterm prelabor rupture of membranes: a double-blind randomized trial. Am J Obstet Gynecol MFM. 2023 May;5(5):100896. doi: 10.1016/j.ajogmf.2023.100896. Epub 2023 Feb 14.

Reference Type DERIVED
PMID: 36796641 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

OBX0034

Identifier Type: -

Identifier Source: org_study_id